CD8A and myeloid sarcoma: After 2 and 4 weeks of therapy, five MS patients showed a tendency for a gradual decrease in MOG-specific CD8+ TCM and TEM (Figures 2B, C), while the remaining cell subsets displayed minor or irregular alternations (Figures 2A, D).